China’s SFDA Lifts Drug License, Bans Principals Over Rabies Vaccine
This article was originally published in PharmAsia News
China's State FDA has found the general manager of Dalian Jingang-Andi Bio-products responsible for the decision to add nucleic acid to the production of human rabies vaccines to lower production costs. The agency also lifted the drug maker's production license and barred its principals from involvement in the pharmaceutical industry for the next 10 years. SFDA emphasized it has not completed its investigation and could implicate still others in the scandal. Although nucleic acid is used as an adjuvant in anti-viral drugs produced in other countries, China has not approved its use in rabies vaccines. (Click here for more
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.